Summary
LLY Chart
Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration
SAN DIEGO--(BUSINESS WIRE)-- #AIinHealthcare--Creyon Bio, Inc. (“Creyon”) today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development and commercialization of novel RNA-targeted oligonucleotide (oligo) therapies for a broad range of diseases. As a part of the collaboration, Creyon will leverage its industry-first AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly's named targets on time.
Eli Lilly: Why Orforglipron Matters, A Lot
Eli Lilly and Company's orforglipron generated positive results in the phase 3 trial in type 2 diabetes patients. The results look good or better than oral semaglutide (across trials) and similar to injectable semaglutide. The importance of these LLY results cannot be understated, as this should be the first oral obesity product that can be produced at scale to satisfy global demand.
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Eli Lilly and Company Dividends
 LLY 2 months ago | Other | €1.32 Per Share |
| LLY 5 months ago | Other | €1.14 Per Share |
| LLY 8 months ago | Other | €1.14 Per Share |
| LLY 11 months ago | Other | €1.14 Per Share |
| LLY 14 Feb 2024 | Other | €1.14 Per Share |
Eli Lilly and Company Earnings
| 1 May 2025 (1 Days) Date | | - Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | 2.7 Cons. EPS | 3.92 EPS |
| LLY 2 months ago | Other | €1.32 Per Share |
| LLY 5 months ago | Other | €1.14 Per Share |
| LLY 8 months ago | Other | €1.14 Per Share |
| LLY 11 months ago | Other | €1.14 Per Share |
| LLY 14 Feb 2024 | Other | €1.14 Per Share |
| 1 May 2025 (1 Days) Date | | - Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | 2.7 Cons. EPS | 3.92 EPS |
Eli Lilly and Company (LLY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Eli Lilly and Company ever had a stock split?
Eli Lilly and Company Profile
| Drug Manufacturers—General Industry | Healthcare Sector | Mr. David A. Ricks CEO | XMUN Exchange | US5324571083 ISIN |
| United States Country | 43,000 Employees | 14 Feb 2025 Last Dividend | 16 Oct 1997 Last Split | 13 Jan 1978 IPO Date |
Overview
Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.
Products and Services
- Diabetes Care
Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.
- Oncology
Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.
- Immunology
Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
- Digestive Diseases
Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.
- Neurological Disorders
Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.
- Other Therapeutic Areas
The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.
Contact Information
